Discover a treatment for SMA that’s directly delivered to the central nervous system to target an underlying cause of motor neuron loss in SMA1,2

have been treated with
SPINRAZA worldwide1*

there’s someone from almost every
age group who has taken SPINRAZA1,2

have been treated with
SPINRAZA worldwide1*

*Based on commercial patients, early access patients, and clinical trial participants through December 2020.
Includes clinical trial patients.
Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients.
§Based on commercial patients in the US (including Puerto Rico) through December 2020.

How does SPINRAZA work?

SPINRAZA is an antisense oligonucleotide designed to
target an underlying cause of motor neuron loss in SMA.1

SPINRAZA has proven efficacy in a broad range of SMA types

SPINRAZA has been studied in the longest clinical trial program in SMA to date.3

The most common side effects of SPINRAZA include lower respiratory infection, pyrexia, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA.

Get to know our patient support

The Biogen SMA360°™ support program provides services for patients and their families that address nonmedical barriers to access.

a later-onset adult patient with spinal muscular atrophy on SPINRAZA

“Around age 32, I had moved across the country and started working with a new doctor. I was feeling weaker but learning to accept it. My doctor mentioned a treatment to me
called SPINRAZA.”